Physician profile
Deepika Jain
NPI 1750551875
$1,661.59
in general payments reported to CMS, 2019-2025
22 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $57.99 · 2021: $58.74 · 2022: $93.72 · 2023: $315 · 2024: $383 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $333.89 | 2024-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $163.38 | 2022-2025 | |
| Glaxosmithkline, LLC. | $155.48 | 2022-2023 | Benlysta, Jesduvroq |
| Nxstage Medical, INC. | $144.81 | 2023 | Liberty Select Cycler, Nxstage System One, Nxstage Cartridge Express |
| Astrazeneca Pharmaceuticals Lp | $101.96 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $97.63 | 2019-2020 | |
| Abbott Laboratories | $91.91 | 2024 | Cardiomems |
| Alexion Pharmaceuticals, INC. | $85.51 | 2019-2020 | |
| Novo Nordisk INC | $79.99 | 2025 | Wegovy |
| Aurinia Pharma U.S., INC. | $71.93 | 2025 | Lupkynis |
| Amgen INC. | $64.67 | 2019-2025 | Tavneos |
| Vifor Pharma, INC. | $40.04 | 2021-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $33.20 | 2020-2025 | Jynarque |
| Strongbridge US INC. | $31.17 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.84 | 2021-2023 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $29.16 | 2019 | |
| Horizon Therapeutics Plc | $28.31 | 2019-2020 | |
| Lilly USA, LLC | $17.32 | 2025 | Jardiance |
| Exact Sciences Corporation | $16.81 | 2024 | Cologuard Collection Kit |
| Fresenius USA Marketing, INC. | $14.95 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.76 | 2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $13.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.